For several human cancers, interfering PD-1 axis has been among the most efficient immunotherapies, and was revealed that PD-1/PD-L-1 inhibition increased anti-tumor T-cell activity through prevention or reversal of exhausted T-cells. This evidence concerns the gene PDCD1 and neoplasm.